The commentary, written by Shweta S. Dipali and Matthew J. Yousefzadeh of Columbia University Medical Center, highlights a study by Sereda and colleagues showing that CMA activity declines during aging and that this decline leads to an enhanced burden of senescent cells. Senescent cells are those that have permanently stopped dividing, usually in response to stress such as DNA damage or telomere shortening. Rather than simply being idle, they remain metabolically active and secrete a potent cocktail of inflammatory cytokines, growth factors, and matrix-remodeling enzymes known collectively as the senescence-associated secretory phenotype. In youth, the immune system patrols tissues and eliminates these cells efficiently. With advancing age, that immunosurveillance falters, senescent cells pile up, and their secretions begin to corrode the surrounding tissue environment.

The mechanistic link between CMA and senescence rests on the peculiar biology of the pathway itself. CMA was first described in 1982, when J. Fred Dice observed that lysosomes could degrade specific cytosolic proteins bearing a particular peptide sequence. Decades later, Ana Maria Cuervo and colleagues defined the machinery: cytosolic chaperones recognize target proteins carrying a KFERQ-like motif, deliver them to the lysosomal membrane protein LAMP2A, which assembles into a translocation complex that threads the unfolded substrate into the lysosomal lumen. Unlike macroautophagy, which sequesters whole regions of cytoplasm into vesicles, CMA is substrate-selective and can be upregulated selectively when cells face proteotoxic stress. This selectivity makes it uniquely suited to degrading the specific proteins that, if left to linger, push cells toward senescence.

Among the substrates that CMA is known to handle are proteins central to senescence signaling. Prior work has shown that CMA can degrade components that stabilize the cell-cycle arrest program, and that loss of CMA activity permits these factors to accumulate. Experimental studies in mice have demonstrated that boosting CMA, for example through gene delivery of LAMP2A, improves function in aging liver, improves cardiac performance, and slows functional decline in models of neurodegeneration. Conversely, blocking CMA in young animals accelerates the appearance of aging-like phenotypes in several tissues. The new analysis by Sereda and colleagues extends this picture by connecting CMA decline to the senescent cell burden itself, positioning the pathway as a gatekeeper that normally restrains the senescence program rather than merely cleaning up after it.

Perhaps the most striking element of the new work is its immunological dimension. The commentary emphasizes that the senescent cell accumulation driven by CMA decline is attributable, in part, to failed macrophage-mediated immunosurveillance. Macrophages are the tissue-resident scavengers of the innate immune system, and in healthy tissue they recognize and engulf senescent cells through a process called efferocytosis, the same engulfment mechanism used to clear apoptotic cells. When macrophages themselves age, their efferocytic capacity diminishes. The new study suggests that CMA decline within macrophages contributes to this failure, creating a vicious cycle: senescent cells accumulate because macrophages cannot clear them, and the inflammatory secretions of those senescent cells further impair macrophage function, deepening the surveillance deficit.

This intersection between autophagy and immunosurveillance reframes how scientists think about the aging immune system. Monocytes and macrophages are not merely passive bystanders in tissue aging; they are active participants whose internal protein quality control determines whether the senescent cell burden is kept in check. If CMA activity in macrophages falls, the cells lose the ability to degrade the proteins that impede their engulfment program, and the tissue loses one of its primary defenses against senescence-driven inflammation. The commentary situates the findings within the broader hallmarks of aging framework articulated by Lopez-Otin and colleagues in 2023, which lists loss of proteostasis, cellular senescence, and altered intercellular communication among the defining features of biological aging. The new work shows how these hallmarks are mechanistically intertwined rather than independent.

The implications for intervention are considerable. Senolytic drugs, which selectively kill senescent cells, have shown promise in early clinical trials for conditions ranging from frailty to diabetic kidney disease. But senolytics address the consequence of senescent cell accumulation, not its cause. If CMA decline is a root driver of that accumulation, then restoring CMA activity could prevent senescent cells from reaching the burden at which they cause harm. Several strategies are already under investigation, including small molecules that upregulate LAMP2A expression, gene therapy approaches that deliver LAMP2A to aging tissues, and lifestyle interventions that have been reported to modulate autophagy pathways. The commentary suggests that such approaches might need to target not only parenchymal cells but also the macrophages whose engulfment program depends on intact CMA.

The findings also raise questions about how CMA decline is regulated during aging. Prior studies have shown that CMA activity falls in many tissues with advancing age, and that this decline correlates with the accumulation of damaged proteins and proteostasis failure. But the signals that trigger the decline, whether oxidative damage to LAMP2A itself, changes in lipid composition of the lysosomal membrane, or systemic factors circulating in aged plasma, remain incompletely understood. The new work adds a layer of complexity by showing that the consequences of CMA decline extend beyond the cell in which it occurs. A macrophage with failing CMA does not merely accumulate damaged proteins; it loses the ability to perform its tissue-level function of clearing senescent cells, and the entire tissue environment deteriorates as a result.

For the aging research community, the study represents a convergence of two previously parallel lines of investigation. Autophagy researchers have long documented the age-related decline of CMA and its role in proteostasis. Senescence researchers have mapped the senescence-associated secretory phenotype and the immune mechanisms that normally clear senescent cells. The new analysis brings these threads together, showing that a single molecular pathway sits at the intersection of proteostasis loss, senescence burden, and immunosurveillance failure. Whether pharmacological restoration of CMA can break the cycle of senescent cell accumulation and macrophage dysfunction in living organisms remains to be tested, but the conceptual framework it provides is likely to shape the design of future studies for years to come.

As the global population ages, the burden of age-related diseases driven by chronic inflammation and tissue dysfunction continues to grow. Understanding the molecular mechanisms that normally restrain senescence, and the reasons those mechanisms fail, is a critical step toward interventions that preserve healthspan rather than merely extending lifespan. The new commentary in Nature Aging makes a compelling case that chaperone-mediated autophagy is one such mechanism, and that its decline with age is not simply a passive consequence of cellular wear but an active contributor to the senescent cell burden that drives systemic aging. If future studies confirm and extend these findings, the pathway may emerge as a promising target for therapies aimed at keeping aging tissues cleaner, calmer, and more functional for longer.

Subject of Research: Cell biology

Article Title: Chaperone-mediated autophagy curbs senescence

Article References: Dipali, S. S., & Yousefzadeh, M. J. (2026). Chaperone-mediated autophagy curbs senescence. Nature Aging. https://doi.org/10.1038/s43587-026-01264-2

Image Credits: AI Generated

DOI: 10.1038/s43587-026-01264-2

Keywords: chaperone-mediated autophagy, cellular senescence, aging, macrophages, immunosurveillance, LAMP2A, proteostasis, senolytics, Nature Aging, efferocytosis, Chaperone-mediated, autophagy

The puzzle the review addresses is a long-standing one. Cellular senescence is a safeguard program: telomere erosion, oxidative damage, oncogene activation, or mitochondrial dysfunction all push cells into a state of permanent growth arrest. Senescent cells adopt a senescence-associated secretory phenotype, or SASP, releasing inflammatory mediators that should flag them for destruction by cytotoxic T cells and natural killer cells. But in aging tissues, these cells persist and multiply. Previous work showed that senescent cells upregulate PD-L1, which engages PD-1 receptors on immune cells and dampens their attack—mirroring the strategy tumors use. What remained unclear was which upstream signals drive PD-L1 upregulation in senescence. Wang and Qin argue that the DNA damage response, a conserved signaling network activated by genotoxic stress, is the key driver.

The DDR can be engaged by multiple senescence-associated stressors. Telomere dysfunction is the most extensively studied: telomeres, the protective caps at chromosome ends, shorten with each round of DNA replication when telomerase is insufficient. When they become critically short, they lose their protective structure and are recognized by the DNA repair machinery as double-strand breaks, initiating a DDR that becomes persistent in replicative senescence rather than transient. Oxidative stress, which accumulates with age, generates reactive oxygen species that damage nuclear DNA and activate the same signaling. Replication stress, arising from conflicts between DNA replication and transcription or from insufficient replication origins, also engages the DDR. In each case, the response persists and shapes cellular behavior well beyond immediate DNA repair—including the regulation of immune checkpoint molecules.

The review details two routes by which DDR signaling elevates PD-L1. The first is transcriptional, through the cGAS-STING pathway. DNA damage can generate cytosolic DNA, including micronuclei that arise from genomic instability. When a micronuclear envelope ruptures, this DNA is sensed by cGAS, triggering STING activation. STING recruits the kinase TBK1, which phosphorylates IRF3, leading to type I interferon production and subsequent PD-L1 transcription. In senescent cells, the same cascade is engaged by cytoplasmic chromatin fragments—bits of chromatin expelled from the nucleus that the cell mistakes for viral DNA. Beyond cGAS-STING, the central DDR kinases ATM and ATR contribute as well: following DNA damage, the ATM/ATR/Chk1 cascade activates STAT1 and STAT3 signaling and induces IRF1 expression, both of which drive PD-L1 transcription. ATM can also enhance PD-L1 through NF-κB activation. The tumor suppressor p53, another central DDR effector, influences PD-L1 in a context-dependent manner that may vary in senescent cells.

The second route is post-translational and operates independently of transcription. The cell cycle inhibitor p16, a hallmark of senescence, inhibits the kinases CDK4 and CDK6. This inhibition limits ubiquitin-dependent proteasomal degradation of PD-L1, stabilizing the protein on the cell surface even when transcriptional input declines. The two mechanisms cooperate: DDR-driven transcription raises PD-L1 production, while p16-mediated stabilization prevents its breakdown. This dual control may render senescent cells inherently difficult for the immune system to clear, because even if one layer of regulation is disrupted, the other can sustain PD-L1 expression.

At the cell surface, PD-L1 exerts its immunosuppressive effects by binding PD-1 on cytotoxic immune cells. Upon engagement, PD-1 recruits the phosphatases SHP-1 and SHP-2, which dephosphorylate key components of the T cell receptor signaling cascade, dampening T cell activation, proliferation, and cytokine production. The same pathway limits natural killer cell cytotoxic function. In aged lungs, p16-positive alveolar macrophages upregulate PD-L1 through this p16-CDK4/6 mechanism, and these PD-L1-high senescent macrophages create an immunosuppressive microenvironment that favors senescent cell accumulation. Single-cell analyses have revealed a correlation between p16 and PD-L1 expression in both immune and epithelial cells, more pronounced in older mice. Notably, senescent cells that display enhanced MHC class I machinery also express PD-L1, suggesting they can present antigens while simultaneously using PD-L1 to engage PD-1 on T cells—potentially driving T cell exhaustion.

In vivo studies provide functional validation. Activating anti-PD-L1 antibodies that engage Fcγ receptors on effector cells can eliminate PD-L1-positive senescent cells and reduce senescence-associated inflammation, both in naturally aged mice and in models of chronic lung inflammation. These findings indicate that PD-L1 is not merely a passive marker of senescence but a functionally relevant checkpoint that actively protects senescent cells from immune elimination—a senolytic vulnerability that could, in principle, be exploited therapeutically.

Recent work has uncovered a second, entirely different function of PD-L1 that operates not at the surface but in the nucleus. A fraction of PD-L1 translocates to the nucleus through an importin-dependent pathway involving the transport factors KPNA2 and KPNA6. Once inside, it binds directly to the cohesin subunit SA1 (STAG1) via its cytoplasmic tail, an interaction required for SA1 nuclear localization and proper telomere maintenance. Depleting either PD-L1 or SA1 produces comparable genomic instability phenotypes—aneuploidy, telomere cohesion defects, and reduced proliferation—and double knockdown shows no synergistic effect, suggesting they act in the same pathway. The circularity is striking: the same telomere dysfunction that triggers DDR and PD-L1 upregulation is also mitigated by PD-L1’s nuclear function. The response is mounted after the damage has occurred and feeds back to limit further damage—a form of damage control that allows a potentially harmful cell to persist while maintaining genomic integrity.

These observations converge on a self-reinforcing circuit. Telomere attrition and other stressors engage a persistent DDR, which upregulates PD-L1 through transcriptional induction and post-translational stabilization. Elevated PD-L1 allows senescent cells to evade immune clearance and accumulate. These cells secrete SASP factors that promote chronic inflammation, and the inflammatory milieu in turn induces DNA damage and telomere dysfunction in neighboring cells—mediated in part by SASP-driven recruitment of neutrophils, which transfer reactive oxygen species to neighboring cells and inflict telomeric damage. Each round amplifies the burden of senescent cells. The system becomes locked in a pro-inflammatory, immunoevasive state: inflammatory signals that should activate immune responses instead reinforce PD-L1-mediated suppression, accounting for the hallmark aging relationship between chronic inflammation and impaired immune function.

Intervention could, in theory, target any node in this loop—dampening DDR signaling, blocking PD-L1, or reducing inflammation—to restore immune clearance and lower senescent cell burden. But significant challenges remain. The causal relationship between DDR signaling and PD-L1 upregulation in vivo has not been fully defined, and whether DDR precedes PD-L1 upregulation in aging tissues or other senescence-associated signals act independently is unclear. The relative contribution of transcriptional versus post-translational mechanisms likely varies across tissues; p16-mediated stabilization has been demonstrated in alveolar macrophages and epithelial cells, but whether it operates with similar efficiency elsewhere remains unknown. Systemic PD-1/PD-L1 blockade carries a risk of autoimmune toxicity, and because the DDR-induced PD-L1 pathway operates in both senescence and cancer, interventions could yield benefits in both contexts or have unintended consequences depending on the cellular environment. Whether these strategies can be safely translated to humans is not yet clear, but the circuit model offers a clear rationale for testing them—and recasts senescence not as a passive endpoint but as an actively maintained, immunoevasive state that might, with the right molecular leverage, be reversed.

Subject of Research: DNA damage response signaling driving PD-L1-mediated immune evasion in cellular senescence and aging

Article Title: DNA damage response as a driver of PD-L1 expression in cellular senescence: implications for immune evasion and immunosenescence

Article References: Wang, Y., & Qin, L. (2026). DNA damage response as a driver of PD-L1 expression in cellular senescence: implications for immune evasion and immunosenescence. Frontiers in Cell and Developmental Biology, 14, Article 1974523. https://doi.org/10.3389/fcell.2026.1974523

Image Credits: AI Generated

DOI: 10.3389/fcell.2026.1974523

Keywords: cellular senescence, DNA damage response, PD-L1, immune evasion, immunosenescence, telomere dysfunction, cGAS-STING, ATM/ATR, p16, SASP, inflammaging, senolytics

The scale of the problem is difficult to overstate. The global economic burden of heart failure reached an estimated 284.17 billion dollars in 2021, split almost evenly between direct medical expenses and indirect costs such as lost productivity. Up to 80 percent of patients experience repeated hospital admissions, and the five-year mortality rate hovers near 50 percent. Despite decades of progress in neurohormonal blockade and guideline-directed therapy, outcomes for many patient subgroups, particularly those with preserved ejection fraction, remain disappointingly static. The authors argue that this therapeutic plateau reflects an incomplete understanding of the molecular machinery driving the syndrome.

Cellular senescence offers one of the most compelling explanations for that gap. Senescent cells have permanently exited the cell cycle yet remain metabolically active, and they accumulate steadily in aging and stressed cardiac tissue. Rather than simply idling, these cells adopt what biologists call the senescence-associated secretory phenotype, or SASP, flooding their surroundings with pro-inflammatory cytokines, chemokines, growth factors, and proteases. This chronic inflammatory milieu damages neighboring cells, promotes fibrosis, disrupts mitochondrial function, and triggers secondary senescence in previously healthy cardiac cells, creating a self-perpetuating cycle of tissue deterioration.

The consequences for cardiac function are specific and measurable. Senescent cardiomyocytes suffer mitochondrial damage, impaired contractility, and metabolic dysfunction, all of which reduce cardiac output and produce the fatigue and exercise intolerance characteristic of heart failure. Senescent endothelial cells and the loss of microvasculature compromise coronary blood flow and oxygen delivery, worsening shortness of breath, angina-like discomfort, and fluid retention. Meanwhile, senescence-driven activation of fibroblasts and abnormal extracellular matrix remodeling stiffen the ventricles, a hallmark particularly of heart failure with preserved ejection fraction. Clinical studies have linked senescence markers to worse outcomes in both ischemic and non-ischemic cardiomyopathies.

Enter sirtuin 1, or SIRT1, a NAD+-dependent class III histone deacetylase encoded on chromosome 10. SIRT1 removes acetyl groups from specific histone lysines, including H3K9ac, H3K14ac, and H4K16ac, compacting chromatin and suppressing transcription at targeted loci. It also deacetylates non-histone regulators such as NF-κB, p53, FOXO transcription factors, and PGC-1α, weaving together control of inflammation, stress resistance, DNA repair, and metabolism. Because its enzymatic activity depends directly on intracellular NAD+ levels, SIRT1 functions as a metabolic sensor, translating the cell’s energy state into epigenetic instructions.

Within the cardiovascular system, SIRT1 is expressed most abundantly in endothelial cells, where it supports nitric oxide production, antioxidant defenses, and angiogenesis while inhibiting endothelial senescence and atherosclerotic progression. In cardiomyocytes, moderate SIRT1 activity activates PGC-1α to drive mitochondrial biogenesis and efficient oxidative phosphorylation, deacetylates p53 and FOXO3a to limit apoptosis, and restrains hypertrophic signaling through the AKT-MTOR and NF-κB pathways while boosting AMPK-dependent metabolic reprogramming. Reduced SIRT1 activity, common in aging, diabetes, obesity, and chronic inflammation, dismantles these protections, elevating reactive oxygen and nitrogen species, damaging mitochondrial DNA, and enhancing TGF-β/SMAD-driven fibrosis.

Yet the relationship is strikingly nonlinear. Mouse studies reveal that SIRT1 behaves as a hormetic regulator, beneficial only within a narrow window. Overexpression at 2.5 to 7.5 times normal levels enhances FOXO-dependent antioxidant enzymes such as catalase and preserves contractile function. But at approximately 12.5-fold overexpression, basal oxidative stress rises, apoptosis and hypertrophy increase, and dilated cardiomyopathy develops, accompanied by mitochondrial depletion and disturbed fatty acid metabolism. Supraphysiologic SIRT1 broadens its deacetylation to many targets, repressing fatty acid oxidation programs and impairing mitochondrial respiration. Too little SIRT1 and too much are both harmful; only the optimal range protects.

Perhaps the most provocative finding the review highlights is that senescence actively destroys SIRT1. Under stress-induced premature senescence, the cell-cycle-regulated ubiquitin ligase complex APC/C-Cdh1 tags SIRT1 for proteasomal degradation, while the protein AROS can competitively prevent this loss. This degradation amplifies SASP gene expression, including interleukin-1 and interleukin-6, feeding the inflammatory fire. Cardiac stress compounds the problem: checkpoint kinase 1 normally phosphorylates SIRT1 at threonine 530, shielding it from SMURF2-mediated ubiquitination, and loss of this protection accelerates mitochondrial dysfunction after ischemia-reperfusion injury. Doxorubicin chemotherapy offers another example, inducing the senescence-associated microRNA miR-34a, which directly represses SIRT1 and activates p66Shc signaling, driving cardiomyocyte death and senescence.

These mechanisms carry immediate therapeutic implications. SGLT2 inhibitors such as empagliflozin and dapagliflozin, now cornerstone heart failure drugs, trigger a fasting-mimicry metabolic state that activates the SIRT1, PGC-1α, and FGF21 axis, promoting autophagy and reducing oxidative stress. Conventional neurohormonal therapies, including ACE inhibitors, ARBs, ARNI, and beta blockers, indirectly reduce the oxidative and inflammatory burdens that SIRT1 also counters, suggesting that SIRT1-based interventions could complement standard care. NAD+ boosters such as nicotinamide riboside and nicotinamide mononucleotide, along with caloric restriction and exercise, may restore SIRT1 activity depleted by aging. Senolytic drugs that clear senescent cells and senomorphics that suppress SASP represent parallel strategies that could pair naturally with SIRT1 modulation.

Significant questions remain before these ideas reach the clinic. Researchers still do not know whether SIRT1 decline precedes senescence or results from it, which cardiac compartment initiates the cascade in different heart failure phenotypes, or whether SIRT1 activation might paradoxically sustain dysfunctional senescent cardiomyocytes in late-stage disease. Most evidence derives from rodent and cellular models, no reliable biomarker of cardiac SIRT1 activity exists in humans, and current SIRT1 activators suffer from poor pharmacokinetics. Single-cell and spatial multi-omics mapping of SIRT1 expression, NAD+ levels, and senescence markers across human heart tissue may resolve these uncertainties. What is already clear, the authors conclude, is that the SIRT1-senescence axis is no longer peripheral to cardiology; it is a central driver of heart failure pathogenesis and a promising target for the next generation of therapies.

Subject of Research: The role of sirtuin 1 in linking cellular senescence to heart failure pathogenesis and therapy

Article Title: Sirtuin 1 is a key molecular link between cellular senescence and heart failure

Article References: Krekora, J., Drożdż, J., & Blasiak, J. (2026). Sirtuin 1 is a key molecular link between cellular senescence and heart failure. Frontiers in Molecular Medicine, 6, Article 1818104. https://doi.org/10.3389/fmmed.2026.1818104

Image Credits: AI Generated

DOI: 10.3389/fmmed.2026.1818104

Keywords: sirtuin 1, cellular senescence, heart failure, SASP, mitochondrial dysfunction, NAD+, senolytics, senomorphics, cardiac aging, endothelial dysfunction, SGLT2 inhibitors, cardiomyocytes

The work was led by Alex Zhavoronkov, a member of the Aging editorial board who is affiliated with Insilico Medicine and the Buck Institute for Research on Aging. Its starting observation is blunt: established frameworks such as the Hallmarks of Aging and Mikhail Blagosklonny’s hyperfunction theory explain mechanisms of decline, but they do not prescribe how, when or whether those mechanisms should be targeted therapeutically. “Existing aging theories describe what changes with age but do not prescribe how to intervene,” the authors write. Control theory, the mathematical discipline concerned with directing dynamic systems toward desired states, offers precisely that prescriptive language.

At the heart of the framework lies the concept of a biological state space, a multidimensional representation of an organism’s condition spanning inflammation, mitochondrial function, epigenetic stability, immune competence and regenerative capacity. Rather than attempting to rewind every molecular feature to a youthful value, the framework prioritizes maintaining or recovering acceptable physiological function. The authors define a functional viability region, the set of biological states in which essential functions remain within acceptable limits, surrounded by a wider recovery region from which safe interventions could potentially restore function. As aging progresses, this recoverable territory may shrink, making functional restoration progressively harder and eventually impossible.

From this geometry follows a striking redefinition of two familiar concepts. Aging, in this framework, is a progressive loss of safe controllability, and biological age is interpreted not as a molecular signature but as the minimum safe cost required to restore or maintain function. This distinguishes the approach from conventional biological aging clocks, which generally estimate chronological age or health-related risk from molecular measurements. Here, the measure of age is practical: how difficult would it be, with the interventions actually available, to achieve meaningful functional improvement without pushing the system into a dangerous state?

Drugs enter the mathematics as vector fields, meaning mathematical descriptions of how an intervention changes a biological system’s trajectory through state space. Because a vector field depends on the current state, the same treatment can push one patient toward recovery and another toward harm. Treatment effects therefore depend on biological state, dose, duration and tissue conditions rather than being universally beneficial. The authors argue that this formulation could help explain why individuals of similar chronological age may respond so differently to the same intervention, a persistent puzzle in geriatric medicine and in trials of aging-related therapeutics.

The framework also delivers a formal account of why treatment order matters. Using mathematical objects known as Lie brackets, which capture how the composition of two influences depends on the sequence in which they are applied, the authors propose that administering two interventions in different sequences can produce different biological effects even when the same therapies are used. To demonstrate the principle, they built a five-variable computational model of an aged mouse liver incorporating senescent-cell burden, oxidative damage, epigenetic integrity, regenerative capacity and fibrosis, and compared three hypothetical strategies: senolytic treatment followed by partial cellular reprogramming, the reverse sequence, and simultaneous administration.

In the illustrative 56-day simulation, senolytic treatment before reprogramming produced the most favorable modeled outcome, with the proposed explanation that clearing senescent cells first creates conditions that improve subsequent reprogramming. The authors are careful about what this proves. These findings came from mathematical simulations rather than animal experiments, and the predicted benefits of treatment sequencing require biological validation before any clinical conclusions can be drawn. The value of the exercise lies in showing that sequencing effects, often treated as anecdotal, can be made explicit, testable predictions within a rigorous formal structure.

Safety occupies the center of the framework rather than its periphery. “Safety is not a secondary penalty appended after efficacy; it is the central constraint that defines the admissible control set,” the authors write. They distinguish between reversible interventions, such as many small-molecule treatments, and potentially durable approaches including gene editing, viral gene delivery and certain cell therapies. Under the framework, reversible interventions are prioritized when uncertainty is high, while longer-lasting therapies are considered only when their expected benefits and safety are sufficiently supported. The approach also acknowledges hard biological boundaries: extensive fibrosis or irreversible cell loss may mark points beyond which available treatments can no longer restore normal function, underscoring the potential importance of intervention timing and of preventive strategies over late-stage rescue attempts.

To explore clinical relevance, the researchers outlined three translational case studies covering immune aging, age-related muscle loss and ovarian aging, illustrating how intervention selection could account for tissue-specific changes, functional goals and safety constraints. A recurring theme is that molecular proxies can mislead: increasing muscle mass, for example, would not constitute successful treatment if strength, mobility and metabolic function remained impaired. The paper also applies an exploratory scoring framework to aging-related interventions across five biological stages, drawing on aging research databases, clinical trials and therapeutic-target resources, and evaluating treatments by biological coverage, safety, reversibility, durability and potential functional benefits. In this exercise, caloric restriction and aerobic exercise ranked highest, followed by the SGLT2 inhibitors dapagliflozin and empagliflozin, with GLP-1 receptor agonists including liraglutide and semaglutide also scoring relatively high. The authors stress that these scores depend on the framework’s assumptions and weighting criteria and do not demonstrate that any of these drugs extend human lifespan or should be prescribed specifically to treat aging.

Looking forward, the paper sketches a proposed computational system that would integrate molecular measurements, clinical data, mathematical modeling and repeated monitoring to estimate biological states and adjust interventions over time, an approach that could eventually support individualized therapeutic decisions, although a fully trained and experimentally validated implementation does not yet exist. The authors also present 20 falsifiable predictions for future investigation, including whether treatment sequencing influences functional restoration, whether biological states predict individual responses, and whether safety-constrained strategies outperform approaches based mainly on aging biomarkers or single molecular targets. The limitations are acknowledged plainly: biological states cannot be measured completely, the models rest on assumptions requiring experimental validation, the rankings depend on chosen scoring criteria, and the framework’s advantages have not been demonstrated in prospective studies. What the paper offers, ultimately, is a shift in attention for aging drug discovery, away from cataloguing age-related changes and toward determining how function might be restored safely, delivered as a set of testable principles that independent laboratories can now begin to challenge.

Subject of Research: A control theory framework for aging biology and safer gerotherapeutic drug discovery

Article Title: New control theory framework proposes a safer approach to aging drug discovery

Article References: New control theory framework proposes a safer approach to aging drug discovery. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: aging, control theory, gerotherapeutics, drug discovery, biological age, senolytics, cellular reprogramming, state space, vector fields, safety, caloric restriction, SGLT2 inhibitors

The study, led by Jieyan Wang, Mengning Yang, and Yifei Li from institutions including Southern Medical University and Xiamen University, combined data from the Web of Science Core Collection and Scopus databases. After merging and deduplicating records, the team deployed a suite of computational tools—Excel 365, CiteSpace, VOSviewer, and the Bibliometrix R package—to construct what they call a bibliometric atlas. The result is not just a literature review but a living map of who is publishing what, where the money and talent are flowing, and which molecular threads are pulling the field forward.

The numbers tell a striking story of acceleration. From 2000 to 2018, annual output remained below 100 papers, a period the authors describe as basic knowledge accumulation. Since 2018, the field has surged past that threshold, reaching a peak of 320 publications in 2025, with total annual citations hitting 8,577. This exponential growth, the researchers argue, signals that kidney aging has evolved from a niche descriptive pursuit into an accelerated phase of breakthrough discovery, driven by an influx of new researchers and shifting molecular paradigms.

Geographically, the landscape remains deeply uneven. The United States dominates with 587 papers and 25,229 citations, while China ranks second in volume with 399 papers but only fourth in citations—a gap the authors interpret as reflecting differences in research quality rather than sheer productivity. The collaboration network analysis identifies the United States as the core node, with the strongest bilateral pathway being US-China collaboration, followed by US-South Korea ties. Germany, though not among the top publishers, ranks second globally in total link strength, highlighting its role as a critical hub connecting the global research network. Meanwhile, the Mayo Clinic leads institutional metrics with 44 papers and 3,651 citations, ahead of the Chinese PLA General Hospital and the University of Pittsburgh.

The journal landscape reveals where the field’s knowledge foundation is anchored. The American Journal of Physiology-Renal Physiology tops the productivity rankings with 50 papers, while the Journal of the American Society of Nephrology and Kidney International each exceed 4,000 co-citations, establishing themselves as the core knowledge base. VOSviewer clustering sorted journals into five academic camps—geriatrics and physiology, clinical correlations, renal immunology, cellular and molecular biology, and drug development—while a dual-map overlay showed that citing journals cluster in molecular biology, immunology, and clinical medicine, with cited journals pointing back toward foundational disciplines like genetics and health sciences.

Among the 16,545 scholars identified, Xiang-Mei Chen from the PLA General Hospital leads in publication volume with 40 papers, while Anette Melk of Hannover Medical School tops citation impact with 379 citations. Yet the field’s social structure reveals a telling weakness: applying Lotka’s Law, the researchers found that over 75 percent of authors have published only a single paper, and the proportion of scholars with sustained output falls well below theoretical predictions. This suggests kidney aging research is still in a phase of rapid expansion and recruitment, lacking the core high-output leaders who typically anchor mature disciplines.

The thematic evolution is perhaps the most striking finding. Keyword analysis established aging (825 occurrences) and cellular senescence (330 occurrences) as the field’s central concepts, but the trajectory of research focus has shifted dramatically over time. Before 2015, keywords like diabetes mellitus, renal disease, and hypertension dominated, reflecting a macroscopic clinical perspective. Between 2016 and 2019, the field pivoted toward mechanistic exploration, with aging, oxidative stress, autophagy, and inflammation rising to prominence. Since 2020, the focus has sharpened to cellular precision—renal tubular epithelial cells, mitophagy, and organelle-level dysfunction—before the most recent emergence of machine learning, ferroptosis, and Mendelian randomization as the defining trends of 2025.

Cellular senescence itself sits at the mechanistic heart of this story. The authors explain that senescent cells—irreversibly arrested but metabolically active—acquire a senescence-associated secretory phenotype (SASP), releasing pro-inflammatory cytokines, chemokines, and profibrotic factors that trigger paracrine senescence in neighboring healthy cells. This self-amplifying cascade fuels extracellular matrix accumulation, nephron loss, and architectural remodeling, establishing a vicious cycle between cellular senescence and whole-organ decline. The translational promise is already visible: the landmark clinical trial by Hickson and colleagues, using the senolytic combination of dasatinib and quercetin to clear senescent cells in patients with diabetic kidney disease, ranks as the most co-cited reference in the entire dataset with 758 citations.

Among the emerging frontiers, ferroptosis—an iron-dependent form of cell death driven by lethal lipid peroxidation—has captured particular attention. In the aging kidney, iron accumulation, exhaustion of the system Xc/GSH/GPX4 axis, and ACSL4-mediated fatty acid enrichment create a heightened vulnerability to this non-apoptotic death pathway. Ferroptosis acts as a preemptive trigger in acute kidney injury and forms a pathological bridge to chronic disease progression by releasing damage-associated molecular patterns and activating innate immune cascades. Meanwhile, the gut-kidney-immune axis has emerged as a transformative paradigm, with uremic toxins like indoxyl sulfate and trimethylamine N-oxide driving premature senescence in proximal tubular cells, while beneficial short-chain fatty acids from commensal bacteria act as endogenous brakes against renal aging.

The convergence of computational intelligence and metabolic regulation, the authors conclude, marks a deep paradigm shift for the field. Machine learning algorithms combined with single-cell RNA sequencing and spatial transcriptomics can now deconvolve senescence heterogeneity across distinct nephron segments, revealing that proximal tubular cells, podocytes, and endothelial cells each follow distinct senescence trajectories. Mendelian randomization, using genetic variants as instrumental variables, is providing causal evidence linking gut microbiota, circulating metabolites, and ferroptosis-related genes to kidney function decline. Together, these approaches promise to transform clinical nephrology from late-stage symptom management into early, data-driven precision geroprotection—turning the aging kidney from an inevitable decline into a targetable biological process.

Subject of Research: Bibliometric mapping of cellular senescence and kidney aging research trends from 2000 to 2025

Article Title: Mapping the aging kidney: a bibliometric atlas of cellular senescence and future frontiers since the 20th century

Article References: Wang, J., Yang, M., Li, Y., Wan, Y., Zhan, X., & Liang, H. (2026). Mapping the aging kidney: a bibliometric atlas of cellular senescence and future frontiers since the 20th century. Frontiers in Nephrology, 6, Article 1905354. https://doi.org/10.3389/fneph.2026.1905354

Image Credits: AI Generated

DOI: 10.3389/fneph.2026.1905354

Keywords: kidney aging, cellular senescence, bibliometric analysis, chronic kidney disease, ferroptosis, machine learning, Mendelian randomization, SASP, mitochondrial dysfunction, gut-kidney axis, senolytics, renal fibrosis

Cellular senescence is often described as a biological emergency brake. When a cell sustains DNA damage, experiences intense stress, or detects aberrant oncogenic signaling, it can enter a state in which it remains metabolically alive but permanently loses the ability to divide. Because uncontrolled proliferation is the defining hallmark of cancer, this arrest is widely regarded as a powerful intrinsic defense mechanism, a tumor-suppressive function inherent to essentially all cells. For decades, researchers have observed senescent cells accumulating in premalignant lesions and interpreted their presence as a reassuring sign that the tissue has contained the threat.

The NYU Abu Dhabi team, working within the University’s Center for Genomics and Systems Biology, set out to test how secure that containment really is. Using a zebrafish model of liver cancer, they examined the earliest responses of cells to a cancer-causing gene, capturing the moment when a normal hepatocyte first confronts oncogenic signaling. Zebrafish are uniquely suited to this kind of question: their livers develop rapidly, their transparency and genetic tractability allow individual precancerous cells to be tracked over time, and the molecular circuitry governing proliferation arrest is broadly conserved with that of humans.

What the researchers found was not a single senescent state but several. Some of the precancerous cells entered what the team describes as terminal senescence, an arrest so deep that the cells can no longer generate tumors under any circumstances examined in the study. Others, however, entered a form of senescence that proved reversible. These cells could regain the ability to divide, re-entering the cell cycle and reacquiring the proliferative potential that, if left unchecked, could contribute to tumor development. In other words, the label senescent concealed two radically different prognoses for the same tissue.

Senior author Kirsten Sadler Edepli, Professor of Biology at NYU Abu Dhabi, framed the finding as a fundamental challenge to how senescence is assessed in both the laboratory and the clinic. Cancer, she explained, is not simply a matter of whether a cell stops dividing or continues to grow. Her team’s data show that there are different types of cellular senescence, and that the type acquired by a precancerous cell can make the difference between whether it ultimately becomes a cancer cell or not. She also emphasized that these different forms of senescent cells respond very differently to treatments, a point she described as critically important when developing and applying cancer therapies.

The therapeutic implications are immediate. Many commonly used chemotherapies do not kill cancer cells outright; instead, they damage them severely enough that the cells enter senescence. The tumor appears contained, but the senescent cells survive, lingering in the tissue. A growing body of oncology research argues that these therapy-induced senescent cells should be eliminated with a second class of drugs known as senolytics, agents designed to selectively kill cells that have entered senescence. The logic is straightforward: remove the arrested cells before they can recover, secrete inflammatory signals, or occasionally slip back into the cell cycle.

But the zebrafish experiments reveal a complication in that logic. When the researchers tested a common senolytic against the precancerous cells in their model, the drug proved effective against only some of the senescent cells and failed to eliminate others. The senolytic was not broadly useless; it simply discriminated between senescent states, clearing one population while sparing another. If the spared population corresponds to the reversible form of senescence identified in the study, then a treatment course that looks successful on paper, with senescence markers dropping and tumor burden appearing controlled, could still leave behind the very cells most capable of reigniting the disease.

This heterogeneity helps explain a persistent puzzle in cancer medicine: why tumors sometimes recur long after treatment has apparently eliminated all visible disease, and why senolytic strategies that succeed spectacularly in one experimental context underperform in another. If senescence is not a monolithic state but a spectrum of arrest programs with distinct molecular underpinnings, then senolytic drugs, which typically target survival pathways that senescent cells depend on, will only work against the subsets of senescent cells that share those dependencies. Accurate classification of senescent states may therefore become as important to treatment planning as the drugs themselves.

The study also carries a message about how precancerous lesions should be interpreted. A liver nodule densely populated with senescence markers has traditionally been read as a lesion that the body has successfully neutralized. The new findings suggest that within such a population, some cells may be irreversibly locked out of the cell cycle while others are merely paused, biding their time with the latent ability to divide again. Distinguishing between these populations at the molecular level could allow clinicians to identify which premalignant lesions warrant aggressive intervention and which can be safely monitored, sparing patients unnecessary treatment.

Beyond its clinical relevance, the work offers a striking example of research training in action. The project was led by Research Scientist Elena Magnani, who mentored several undergraduate students through their capstone research projects, and Sadler Edepli highlighted their contribution to the discovery, noting that students can play a valuable role in high-impact research when given the opportunity to engage directly with important scientific questions and dedicated mentors to guide their efforts. As the field moves toward senescence-subtype-aware therapies, the study’s central insight stands out: the same oncogene, acting in the same tissue, can produce cells that guard against cancer and cells that quietly prepare for it, and only therapies that respect that difference are likely to finish the job.

Subject of Research: Heterogeneous cellular senescence responses to oncogene activation in a zebrafish liver cancer model

Article Title: NYU Abu Dhabi study reveals how cells respond differently to a cancer-causing gene

Article References: NYU Abu Dhabi study reveals how cells respond differently to a cancer-causing gene. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cellular senescence, oncogene, liver cancer, zebrafish model, senolytics, tumor suppression, precancerous cells, EMBO Reports, cancer therapy, NYU Abu Dhabi, cell cycle re-entry, chemotherapy-induced senescence

Researchers at Heinrich-Heine-University Düsseldorf, led by Dennis Sohn and colleagues, report that pediatric medulloblastoma cells carrying functional, wild-type p53 do not simply die when bombarded with gamma irradiation. Instead, many of them enter senescence, a terminal and stable arrest of the cell cycle. These zombie-like cells stop dividing but refuse to die, lingering in the tissue for weeks. Crucially, the team showed that these irradiated, senescent tumor cells can then be selectively wiped out with senolytic drugs—compounds designed to eliminate senescent cells. The finding opens a potential two-step strategy: radiation first drives susceptible tumor cells into senescence, and senolytics then clear them away.

The study compared two SHH-activated medulloblastoma cell lines with fundamentally different genetic backgrounds. ONS76 cells carry wild-type p53, the master tumor suppressor that decides a cell’s fate after catastrophic DNA damage. UW228-3 cells carry a mutated, dysfunctional p53. When both lines were exposed to a 20 Gy dose of gamma irradiation, their responses diverged dramatically. UW228-3 cells detached from the culture dish and degraded completely within three to seven days. ONS76 cells, by contrast, remained attached for more than fifty days, flattening out and swelling enormously in both cell body and nucleus—classic hallmarks of senescence.

The molecular evidence followed the morphology. Irradiated ONS76 cells showed a dose-dependent stabilization of p53 and a strong increase in p21, the cyclin-dependent kinase inhibitor encoded by the CDKN1A gene that enforces the senescence arrest. They also accumulated senescence-associated beta-galactosidase activity, a lysosomal enzyme widely used as a senescence marker, and built up lipofuscin, the pigment-like cellular debris characteristic of aged or senescent cells. When the researchers knocked down p53 or p21 using siRNAs, the senescence program collapsed: far fewer cells became senescent and substantially more died instead. This established that radiation-induced senescence in these cells is strictly p53/p21-dependent.

The p53-mutated UW228-3 cells told the opposite story. They showed only a faint, transient rise in beta-galactosidase activity and never developed senescent morphology. Instead, measurements of lactate dehydrogenase release—a marker of plasma membrane destruction—and of DEVDase-like caspase activity revealed that they died by apoptosis, the controlled self-destruction pathway. A pan-caspase inhibitor, q-VD-OPh, completely abolished this cell death while leaving senescence untouched in the wild-type line. The team also employed a recently developed fluorescent lipofuscin binder, GLF16, alongside the amine-reactive viability dye Zombie-violet, allowing simultaneous flow cytometric quantification of senescent and dead cells with sharper discrimination than traditional staining.

The researchers then turned to c-Myc, a proto-oncogene that serves as a crucial negative prognostic factor in medulloblastoma and is known to antagonize p21. Using engineered ONS76 and UW228-3 lines that constitutively overexpress c-Myc, they found that the oncogene tipped the balance away from senescence. In irradiated ONS76/c-Myc cells, p21 protein levels dropped—though p21 mRNA levels did not, indicating that c-Myc interferes with p21 protein production or stability rather than its transcription. Fewer cells adopted senescent morphology, and more cells died, a death that q-VD-OPh could block even though it was not accompanied by elevated caspase activity. Notably, this c-Myc effect operated independently of p53 status. The senescent population in c-Myc-overexpressing cells also proved far more resistant to senolytic treatment, underscoring how oncogene dosage can shape therapeutic vulnerability.

The therapeutic payoff came in the final set of experiments. Seven days after irradiation, when the ONS76 cultures had become fully senescent, the researchers treated them with four senolytic compounds: the BCL-2 family inhibitors Navitoclax and Venetoclax, and the PI3K inhibitors PX-866 and BAY 80-6946 (Copanlisib), the latter already FDA-approved. All four killed the senescent cells in a dose-dependent manner. Navitoclax, however, also eliminated proliferating cells at the highest concentration tested, 30 µM—a reminder of the well-known toxicity problem that has complicated its clinical use, since healthy non-senescent cells are targeted at higher doses. The PI3K inhibitors, by contrast, showed a cleaner specificity for the senescent population.

The clinical logic behind this approach is compelling. Medulloblastoma is unusual among cancers in that relatively few tumors harbor p53 mutations, and in the SHH-activated subtype, p53 status actually defines two distinct risk groups: p53-mutated tumors carry a five-year overall survival of roughly 41 percent and are classified as high risk, while p53 wild-type tumors fare far better at about 81 percent. The new findings suggest that these two groups respond to radiotherapy in mechanistically different ways—senescence in the wild-type setting, apoptosis in the mutated one—a distinction invisible to standard proliferation-based cytotoxicity assays. Senolytic combination therapy would therefore primarily apply to the intermediate-risk, p53 wild-type group, where it could potentially improve outcomes further while reducing the radiation dose needed for tumor control.

The broader context strengthens the case. Senescent cells are not inert; they secrete a cocktail of cytokines and chemokines known as the senescence-associated secretory phenotype, or SASP, which drives chronic tissue microinflammation and can support tumor relapse. Craniospinal irradiation is associated with accelerated brain aging in survivors, and studies in glioblastoma have already shown that eliminating therapy-induced senescent cells with Navitoclax attenuates recurrence. Mouse studies of whole-brain irradiation likewise suggest that senolytic clearance protects cognitive function and the blood-brain barrier. Because senescence can be triggered at lower radiation doses than outright cell death, pairing senolytics with craniospinal irradiation might one day allow clinicians to cure tumors with less radiation exposure while simultaneously mopping up the senescent cells that radiation leaves behind.

Important caveats remain. The entire study was conducted in cell lines rather than animal models or patients, and the exact nature of the c-Myc-driven, caspase-inhibitable cell death observed in the overexpressing cells is still unclear. The authors themselves note that it would be intriguing to test whether JQ1, a bromodomain inhibitor that suppresses c-Myc signaling, could push c-Myc-high, p53 wild-type medulloblastoma cells back into a senescence-permissive state and thereby restore their susceptibility to senolytics. Still, the work is the first to document radiation-induced senescence in medulloblastoma cells and to demonstrate that these cells can be eliminated with existing senolytic drugs. If the strategy survives translation into preclinical models, it could reshape how one of pediatric oncology’s most grueling treatments is delivered—turning the very cells that radiation strands between life and death into targets for a second, cleaner strike.

Subject of Research: Radiation-induced cellular senescence in pediatric medulloblastoma and its targeting by senolytic drugs

Article Title: p53 wild-type/low c-Myc-expressing ONS76 pediatric medulloblastoma cells become senescent after gamma-irradiation and can be eliminated by senolytic substances

Article References: Sonntag, J., Preugschas, R.-L., Jazmati, D., Qin, N., Neuwahl, J., Matuschek, C., Remke, M., Budach, W., Hörner-Rieber, J., & Sohn, D. (2026). p53 wild-type/low c-Myc-expressing ONS76 pediatric medulloblastoma cells become senescent after gamma-irradiation and can be eliminated by senolytic substances. Cell Death Discovery, 12(1), Article 410. https://doi.org/10.1038/s41420-026-03404-4

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03404-4

Keywords: medulloblastoma, senescence, senolytics, p53, c-Myc, p21, gamma irradiation, craniospinal irradiation, Navitoclax, PI3K inhibitors, SASP, pediatric brain tumor

The team, led by corresponding author Chunshui Zhou, focused on a small molecule called SMIP004, a compound previously known to act on mitochondria, the energy-producing organelles inside cells. In a small-scale chemical screen run against senescent cancer cells, SMIP004 stood out for its ability to selectively kill TIS cells while sparing normally proliferating ones. That selectivity is the holy grail of senolytic drug development: any agent that clears senescent cells must not simultaneously damage healthy tissue or the still-vulnerable bulk of the tumor. Understanding why SMIP004 showed this preference became the central question of the study, and the answer led the researchers deep into the metabolic rewiring that defines the senescent state.

The key player turned out to be PDHA, the catalytic subunit of the pyruvate dehydrogenase complex, a mitochondrial enzyme that occupies one of the most important crossroads in cellular metabolism. Pyruvate, the end product of glycolysis, stands at a fork in the road: it can be converted to lactate in the cytoplasm, as happens in many cancer cells even in the presence of oxygen, or it can be funneled into the mitochondria by PDHA, feeding the citric acid cycle and oxidative phosphorylation. The researchers discovered that in therapy-induced senescent cancer cells, PDHA protein is unusually stable, and that this stabilization depends on elevated activity of AMPK, the AMP-activated protein kinase that serves as the cell’s master energy sensor. When energy is scarce, AMPK switches on catabolic programs and dials down anabolic ones; in senescent cells, the team found, AMPK activity keeps PDHA protected from degradation, effectively locking the senescent cells into a particular mitochondrial metabolic configuration.

SMIP004, remarkably, does not touch AMPK itself. Instead, the compound promotes the ubiquitin-mediated degradation of PDHA, stripping away the stabilized enzyme and collapsing the metabolic adaptation that senescent cells depend upon. The researchers demonstrated this relationship with elegant complementary experiments. When they activated AMPK with metformin, the widely used diabetes drug, proliferating cells began stabilizing ectopically expressed PDHA — and SMIP004 treatment could reverse that stabilization. Even more decisively, when the team mutated the AMPK phosphorylation sites on PDHA, the stabilization was abolished altogether. Together, these results establish a clean causal chain: AMPK activity stabilizes PDHA through its phosphorylation sites, and SMIP004 short-circuits that protection by pushing PDHA into the degradation machinery, independent of AMPK.

The consequences for senescent cancer cells are catastrophic. With PDHA destabilized, the cells’ mitochondrial metabolism falters, and at low doses SMIP004 induces what the authors describe as an energy crisis, culminating in massive apoptosis. Because senescent cells have become metabolically dependent on the AMPK–PDHA axis, they are far more vulnerable to this disruption than proliferating cells, which retain the flexibility to compensate. This dependency creates a therapeutic window: a dose of SMIP004 that leaves normal dividing cells largely unharmed can wipe out the senescent survivors that chemotherapy leaves behind. It is a textbook example of synthetic lethality emerging from a state-specific metabolic liability — the very principle that has driven success in other areas of targeted cancer therapy.

The most clinically compelling results came from mouse experiments. When the researchers combined SMIP004 with doxorubicin, a mainstay anthracycline chemotherapy drug, the combination suppressed tumor growth more effectively than chemotherapy alone, eliminated p21-positive cells — p21 being a canonical marker of senescence — and reduced metastatic lesions in tumor-bearing animals. This is precisely the outcome a senolytic strategy is designed to achieve: the cytotoxic drug generates the senescent population, and the senolytic agent clears it before those cells can contribute to relapse or spread. The finding that a senolytic can measurably reduce metastatic burden is particularly notable, since metastasis remains the leading cause of cancer mortality and is notoriously difficult to prevent with conventional approaches.

To explore the biology at single-cell resolution, the team performed single-cell RNA sequencing, which revealed that elevated transcription of PDHA is associated with senescence-like tumor cells. This observation ties the protein-level stabilization story to a broader transcriptional program: senescent tumor cells do not merely accumulate PDHA protein through post-translational protection, they also upregulate its expression, suggesting that the enzyme sits at the heart of the senescent phenotype rather than being an incidental passenger. The convergence of transcriptomic and biochemical evidence strengthens the case that PDHA is a genuine vulnerability of TIS cells and not an artifact of a single experimental system.

The human relevance of the findings received support from clinical tissue analysis. The researchers found that the expression of both PDHA and p21 is enhanced in tumors following chemotherapy, and that higher expression of these markers correlates with poor patient survival. In other words, the senescent population the study targets is not a laboratory curiosity — it appears in real patients after real treatment, and its presence tracks with worse outcomes. That correlation does not prove causation, but it is exactly the kind of biomarker evidence that justifies pursuing PDHA-targeted senolytics toward the clinic, and it suggests that PDHA and p21 could serve as pharmacodynamic markers to identify patients most likely to benefit from a combination regimen.

The study also carries broader implications for how scientists think about the metabolic identity of senescent cells. AMPK is often portrayed as a tumor-suppressive, health-promoting signal — metformin’s putative anti-cancer reputation rests partly on AMPK activation — yet this work shows that the same pathway can be co-opted by senescent tumor cells to stabilize a key metabolic enzyme and sustain their survival. The lesson is that context matters enormously: a pathway that protects healthy cells from metabolic stress may simultaneously protect damaged, treatment-altered tumor cells from elimination. It also highlights the value of unbiased chemical screening paired with proteomic analysis, an approach the team pursued with support from the Gygi laboratory’s proteomics expertise at Harvard, which can uncover mechanisms that hypothesis-driven work might never have targeted.

Considerable work remains before SMIP004 or any derivative could reach patients. The compound was identified in a small-scale screen, and its precise molecular target within the ubiquitin degradation machinery, its pharmacokinetic profile, and its safety in combination regimens all require further definition. Dosing in mice will need careful translation, and senolytics as a class raise questions about long-term effects, since senescent cells also play roles in wound healing and tissue repair. Still, the study delivers a complete conceptual arc: a defined metabolic dependency of therapy-induced senescent tumor cells, a small molecule that exploits it through a clearly delineated mechanism, and preclinical evidence that combining the compound with standard chemotherapy improves outcomes while reducing metastasis. If the AMPK–PDHA axis proves to be a general feature of senescent tumor cells across cancer types, the strategy described by Zhou and colleagues could become a template for a new generation of adjuvant therapies — drugs that do not attack the tumor directly, but instead clean up the dangerous residue that treatment leaves behind.

Subject of Research: Selective elimination of therapy-induced senescent tumor cells with the senolytic compound SMIP004 via blockade of AMPK-dependent PDHA stabilization

Article Title: Small mitochondria-targeting compound SMIP004 selectively eliminates therapy-induced senescent tumor cells by blocking AMPK-dependent PDHA stabilization and improves the outcomes of chemotherapy

Article References: Zhang, M., Piao, S., Song, Y., Zhao, N., Liu, A., Fu, S., Sun, W., Qiu, X., Zhang, J., Paulo, J. A., Yang, Y., Gygi, S. P., Xu, H., & Zhou, C. (2026). Small mitochondria-targeting compound SMIP004 selectively eliminates therapy-induced senescent tumor cells by blocking AMPK-dependent PDHA stabilization and improves the outcomes of chemotherapy. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03395-2

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03395-2

Keywords: senolytics, therapy-induced senescence, SMIP004, PDHA, AMPK, mitochondria, chemotherapy, doxorubicin, tumor recurrence, metastasis, p21, apoptosis

Cellular senescence is a state in which cells permanently stop dividing but refuse to die. First described in 1961 by Leonard Hayflick and Paul Moorhead, senescence was once viewed as a simple safeguard against cancer. Scientists now understand it as a far more complex condition: senescent cells suffer mitochondrial dysfunction, oxidative stress, and DNA damage, and they secrete a potent cocktail of inflammatory and fibrotic molecules known as the senescence-associated secretory phenotype, or SASP. Factors such as interleukin-6, tumor necrosis factor alpha, and transforming growth factor beta can spread inflammation and even push neighboring cells into senescence themselves, creating a self-amplifying cycle of tissue deterioration.

In the heart, this matters enormously. Senescent cardiomyocytes—the contractile muscle cells—show impaired shortening, defective calcium handling, and resistance to apoptosis through pro-survival pathways. Senescent fibroblasts and endothelial cells contribute to fibrosis and maladaptive remodeling. Together, these changes stiffen the left ventricle, impair its relaxation, and set the stage for heart failure, particularly the diastolic form in which the heart fills poorly despite pumping adequately. Prior work had shown that senolytic drugs such as dasatinib plus quercetin, or the BCL-family inhibitor navitoclax, could clear senescent cardiac cells when given to already-aged mice, but the chronic, preventive effects of these drugs on the heart remained largely unexplored.

The research team, based at McMaster University, set out to close that gap with an unusually long experiment. They began treating twelve-month-old mice—roughly early middle age in mouse terms—with one of four regimens for nine months: a vehicle control, biweekly oral doses of dasatinib plus quercetin, twice-weekly treadmill exercise sessions, or both interventions combined. By the end of the study, the animals had reached twenty-one months of age, the threshold of old age. A separate cohort of four-month-old young mice served as a healthy benchmark. Crucially, both male and female mice were included, and the investigators reported no significant sex differences in any outcome.

The functional results were striking. Using high-frequency ultrasound, the researchers measured how quickly the left ventricle relaxed between beats—the isovolumetric relaxation time—and combined contraction and relaxation measures into the myocardial performance index, a sensitive gauge of overall cardiac health. Naturally aged control mice showed relaxation times roughly 40 percent longer and performance indices about 44 percent higher than the best-performing treatment groups, indicating substantially worse myocardial function. Exercise-treated mice also displayed a markedly better E/A ratio, a frontline marker of diastolic filling, suggesting that aerobic training preserved the ventricle’s ability to relax and fill with blood. Notably, systolic measures such as ejection fraction were largely preserved across all aged groups, reinforcing the growing view that diastolic decline, not systolic failure, is the dominant functional signature of the aging heart.

Beneath those functional improvements lay a cellular story. Using immunofluorescence to detect the canonical senescence markers p16, p21, and gamma-H2AX—a marker of DNA damage—the team counted labeled cardiomyocytes and interstitial cells across four regions of each heart. Exercise reduced p16-positive cardiomyocytes by 29 percent, senolytics by 21 percent, and the combination by 27 percent compared with aged controls. Similar reductions appeared for p21, with exercise cutting positive cardiomyocytes by nearly half, and for gamma-H2AX, where the combined intervention lowered DNA-damage-positive cells by 36 percent. Interstitial cells followed the same pattern. The researchers also found that p21 expression was highest in the central left ventricle and lower at its anterior and posterior edges, revealing a spatial heterogeneity in cardiac senescence that whole-tissue analyses can easily miss.

Perhaps the most compelling finding was correlational: across all animals, the abundance of p16- and p21-positive cells tracked closely with worse cardiac function. Higher marker levels were associated with longer relaxation times, higher myocardial performance indices, and lower cardiac output and stroke volume, with correlation coefficients reaching 0.53. Marker expression was also coordinated across cell types—p21-positive cardiomyocytes and interstitial cells correlated with a striking r of 0.91—suggesting that senescence in the aging myocardium behaves as a tissue-wide phenomenon rather than a collection of isolated bad cells. This statistical link between senescent burden and functional decline strengthens the causal plausibility of the interventions, even though correlation alone cannot prove mechanism.

The study was not without surprises. At the whole-heart level, neither exercise nor senolytics significantly reduced p16 or p21 protein expression, and mRNA results were inconsistent, with the combined group paradoxically showing elevated p53 gene expression. Canonical SASP factors measured in heart tissue and serum—using western blotting, quantitative PCR, and the sensitive Olink proteomics panel—showed no differences between young, aged, and treated animals. The authors suggest several explanations: whole-heart lysates dilute cell-specific signals, twenty-one months may be too early for a pronounced SASP surge, and cardiac cells may secrete atypical SASP profiles dominated by fibrotic and hypertrophic factors rather than classic inflammatory cytokines. The disconnect between cellular and whole-tissue measurements is itself informative, indicating that senolytic and exercise effects are most visible at the single-cell level during early old age.

Equally notable was what did not happen: combining the interventions produced no additive benefit. Exercise and senolytics each worked about as well alone as together, contradicting the researchers’ initial hypothesis. One possibility is that both interventions converge on the same downstream targets—the p16, p21, and p53 pathways and inflammatory signaling—so that once senescent cell clearance reaches a ceiling, adding a second tool yields diminishing returns. Another is that at twenty-one months, the pool of senescent cells is still moderate; exercise during the off-weeks of the intermittent senolytic schedule may have already depleted the cells that dasatinib and quercetin would otherwise have cleared. The timing of treatment relative to senescence accumulation may therefore be decisive, and the authors caution that early senolytic use could theoretically remove cardiomyocytes from a tissue with minimal regenerative capacity.

The broader implications are tantalizing. This is the first demonstration that aerobic exercise can act as a natural senolytic in the aging heart, extending earlier findings in skeletal muscle and in young animals. It is also the longest senolytic intervention yet tested in cardiac tissue, showing that preventive, rather than rescue, administration of dasatinib plus quercetin can limit senescent cell accumulation over most of a mouse’s adult life. For a rapidly aging human population facing rising rates of heart failure with preserved ejection fraction, the message is doubly appealing: one intervention is already available in every gym, while the other is advancing through the emerging field of geroscience. The authors emphasize that long-term efficacy, optimal dosing, and systemic effects must be validated before clinical translation, but the vision of preserving cardiac function by targeting the cellular biology of aging itself has moved a meaningful step closer to reality.

Subject of Research: Effects of chronic senolytic treatment and aerobic exercise on cellular senescence and myocardial function in the aging mouse heart

Article Title: Chronic Senolytic Treatment and/or Aerobic Exercise Reduce Senescence and Improve Myocardial Function During Aging in the Heart

Article References: Bevington, R. T., Johnson, A. L., Hockey, B. L., Fajardo, V. A., & Parise, G. (2026). Chronic Senolytic Treatment and/or Aerobic Exercise Reduce Senescence and Improve Myocardial Function During Aging in the Heart. Aging Cell, 25(10), Article e70759. https://doi.org/10.1111/acel.70759

Image Credits: AI Generated

DOI: 10.1111/acel.70759

Keywords: cellular senescence, senolytics, dasatinib, quercetin, aerobic exercise, aging heart, myocardial function, cardiomyocytes, SASP, diastolic function, p16, p21

The biological premise behind the trial rests on one of the hallmarks of ageing: cellular senescence. Senescent cells are cells that have essentially permanently stopped dividing, usually in response to stressors such as DNA damage, oxidative stress or oncogenic signalling. In the short term, senescence is useful — it helps wounds heal and stops damaged cells from becoming cancerous. But when senescent cells linger, they become a problem. They resist apoptosis through activated anti-death pathways, evade clearance by the immune system, and pump out a cocktail of proinflammatory and profibrotic signalling molecules collectively known as the senescence-associated secretory phenotype. In the liver, this chronic inflammatory noise has been implicated in driving both the inflammation and the fibrogenesis that define MASH, and senescence signatures have also been documented in alcohol-associated hepatitis and primary sclerosing cholangitis.

Senolytic drugs exploit a specific vulnerability. Because senescent cells depend on particular prosurvival networks to avoid dying, drugs that interfere with those networks can selectively eliminate them while sparing healthy, proliferating cells. Dasatinib, an approved tyrosine kinase inhibitor, and quercetin, a naturally occurring flavonoid, target complementary senescence-associated survival pathways, and the pairing emerged from transcriptomic analyses showing which survival nodes senescent cells rely on most. Earlier phase-1 studies in idiopathic pulmonary fibrosis and diabetic kidney disease had suggested that intermittent dosing could reduce senescent cell burden in humans with an acceptable safety profile, but no one had yet shown that this approach could change liver histology in MASH.

The Amsterdam trial enrolled 31 participants with biopsy-proven fibrotic MASH, with a median age of 56 years; 76 percent were male and 58 percent had type 2 diabetes. Participants were randomized one-to-one to receive either dasatinib 100 milligrams per day plus quercetin 1,000 milligrams per day, or matching placebo. The dosing schedule was deliberately intermittent: three consecutive days per week for three weeks, followed by a four-week drug-free period, with the seven-week cycle repeated three times. The logic is that senescent cells take weeks to redevelop and do not divide, so brief pulses of treatment should be enough to clear them while limiting cumulative drug exposure. Twenty-seven participants completed the study, and all randomized participants were included in the intention-to-treat analysis, with those who discontinued counted as non-responders.

The primary endpoint was demanding: at least a one-stage improvement in fibrosis score on the Steatosis Activity Fibrosis system without any worsening of MASH, assessed on paired liver biopsies read centrally by three blinded pathologists. Forty-seven percent of participants in the treatment arm met this endpoint versus 7 percent on placebo, an absolute difference of 40 percentage points with a P value of 0.021. MASH resolution — improvement in the hepatocyte ballooning that defines the disease — occurred in 53 percent of treated patients versus 7 percent of controls, and the NAFLD Activity Score fell substantially more in the treated group. The SAF-activity score also improved significantly, while improvement on the EPoS fibrosis staging system showed a similar directional trend that narrowly missed statistical significance.

What elevates the trial beyond a simple histological result is the molecular layer. The team performed single-nucleus RNA sequencing on 53 frozen liver biopsy samples, profiling gene expression in individual liver cells before and after treatment. Because canonical senescence markers such as p21, p16 and p53 were expressed at low levels in the sequencing data, the researchers used curated gene signatures — the SenMayo set and a senescent hepatocyte gene signature — to capture senescence activity across the tissue. In the treated group, both senescence signatures were significantly depleted by the end of the study, while the placebo group showed no such change or even the opposite pattern.

The sequencing also revealed a striking remodelling of the cellular composition of the liver. Treated participants showed a significant reduction in the proportional abundance of hepatic stellate cells — the fibrogenic workhorses of the liver — along with decreases in myeloid cells, B cells and T cells, accompanied by a relative increase in hepatocytes. Mixed-effects logistic regression confirmed the reduction in immune cell and stellate cell presence. A fibrosis gene signature, including collagen genes COL1A1 and COL1A2, the profibrotic signalling molecule TGFB1 and the stellate cell activation marker ACTA2, was significantly downregulated after treatment, whereas the placebo group showed enrichment of the same fibrosis program. Notably, no cancer-related transcriptional pathways were enriched despite the reduced senescence signatures, an important check given that hepatocyte senescence can both suppress and, in some contexts, promote tumour development.

Safety findings were nuanced. Adverse events were significantly more frequent in the treatment group, affecting 82 percent of participants versus 43 percent on placebo, with headache the most commonly reported complaint in the treated arm. However, nearly all events were mild to moderate and self-limiting, and there were no cases of myelosuppression or QTc prolongation — the cardiac and bone marrow toxicities most feared with dasatinib. One serious adverse event, a planned knee operation, was deemed unrelated to treatment, and one severe event involving difficulty swallowing was traced to an oesophageal malignancy in a participant who had not disclosed an active oncological condition during screening. On quality-of-life questionnaires, treated participants reported significantly better general health on the SF-36, though most other domains showed no significant differences.

The authors are candid about the limitations. The number of responder events was small, producing a wide confidence interval around the relative risk of 6.59 whose lower bound approached the null. Four sensitivity analyses using different assumptions about missing biopsy data consistently preserved the direction of the effect, with relative risks ranging from 3.29 to 9.06, and statistical significance held in three of the four scenarios; only the most conservative worst-case analysis failed to reach significance. The team emphasizes that the histological response finding should be considered hypothesis-generating rather than confirmatory pending replication in a larger trial. The 21-week follow-up is also short for a fibrosis endpoint, and the modest sample size limited the ability to detect changes in non-invasive markers such as FIB-4, liver stiffness measurements and the enhanced liver fibrosis test, which did not differ between groups.

Even with those caveats, the implications are considerable. Metabolic dysfunction-associated steatotic liver disease is the most common liver disorder worldwide, with an estimated prevalence approaching 40 percent, and fibrosis stage is the strongest predictor of liver-related complications and mortality. Current approved therapies for MASH act primarily on metabolic drivers, whereas the single-cell data here suggest that senolytics may strike at the fibrogenic machinery itself, depleting stellate cells and inflammatory populations rather than merely resolving steatosis as a secondary effect. The antifibrotic reach of senolytics may extend beyond the liver, with prior studies reporting benefits in idiopathic pulmonary fibrosis and diabetic kidney disease. The Amsterdam team argues that future trials must now define optimal dosing, cycle number, drug-free intervals, patient selection and long-term safety — but the proof of principle, that ageing cells can be evicted from a scarred human liver and that the tissue responds by healing, has now been demonstrated under blinded, randomized, placebo-controlled conditions.

Subject of Research: Senolytic therapy with dasatinib and quercetin for fibrotic metabolic dysfunction-associated steatohepatitis

Article Title: Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial

Article References: Koning, M., Kovynev, A., Fondevila, M. F., Ruhe, E. J. M., Mommersteeg, M. C., Ramakers, C., Hutten, B. A., Verwer, B., Vlug, M., Kuiper, T., van den Berg, M., Vrieze, A., Bizino, M., van den Beld, A., Berk, L., Boerlage, T., Augustijn, Q. J. J., Brouwer, W. P., Chen, W. J., … Meijnikman, A. S. (2026). Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial. Nature Metabolism. https://doi.org/10.1038/s42255-026-01643-4

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01643-4

Keywords: senolytics, dasatinib, quercetin, MASH, liver fibrosis, cellular senescence, randomized controlled trial, hepatic stellate cells, single-nucleus RNA sequencing, Nature Metabolism, fatty liver disease, senescence-associated secretory phenotype